EU’s IVDR Clinical Evidence Comes Under The Microscope
Do you know what is required when it comes to providing clinical evidence for IVDs in the EU? Consultants at Maetrics explain how, given that the majority of IVDs are about to find themselves in a higher risk class, there is a steep learning curve ahead. There will also be a scramble for the limited notified body resources available.
You may also be interested in...
An expert panel at the AdvaMed Digital MedTech Conference discussed the impact of new privacy rights and data protection, in particular CCPA and GDPR, on medtech companies and ways for companies to deal with the challenge of compliance.
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.